Gilead Sciences stock continues downward trend amid oversold signals and resistance at 132.29

Traders Union
All News
Companies
Gilead Sciences slides 1.85% today

Highlights

Gilead Sciences is trading well below major moving averages, reflecting sustained bearish pressure across timeframes.
Momentum indicators show oversold conditions and negative signals, confirming weak participation and dominance by sellers.
Price is expected to consolidate between $124.00 and $128.50 next week, with a break below $124.00 risking renewed downside toward yearly lows.

Selling pressure dominates as price holds under key moving averages

Gilead Sciences ($GILD) is trading well below its main moving averages, with the current price of $125.73 positioned under the MA-20 ($131.55), MA-50 ($134.01), and MA-200 ($128.97), underscoring persistent pressure from sellers across short-, medium-, and long-term perspectives. The Ichimoku Kijun level on D1 stands at $132.29, marking immediate resistance above the current price. Near-term support is found at the MA-200 ($128.97), with key support at the MA-100 ($138.61). Immediate resistance sits at the Kijun ($132.29), followed by the MA-50 ($134.01) as key resistance.

Oversold conditions persist as bearish momentum drives weekly decline

Momentum signals on D1 remain negative, with MACD in "Sell" territory and ADX reflecting a weak, neutral trend, suggesting little conviction behind the move. RSI (39.92), Stoch RSI (10.12), and CCI (–101.97) all indicate oversold conditions, while BBP (–0.01) confirms sellers are dominating intraday action. The AO further supports the bearish tone. GILD has fallen $3.43 (2.67%) over the past week, slipping from a prev_week_close of $129.16, and is currently at the very bottom of its weekly range, with weekly volatility at 3.56%. In today’s session, the stock is down 1.85%, marking a clear continuation of the recent downward move and confirming a steady decline from the weekly high.

Further downside likely as weak indicators cap rebound prospects

Looking ahead, the expected price range for the coming week is $124.00 to $128.50, which aligns with recent volatility and keeps the stock above its 52-week low ($104.46) but well below the high ($157.29). Based on W1 indicators, there is a very low probability (less than 20%) of a near-term price increase, making further declines the more likely scenario. Baseline expectations are for sideways consolidation near support. A bullish scenario would require a sustained move above $132.29 to challenge higher resistance, while a bearish break below $124.00 could open the way for further downside toward prior yearly lows.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that analysts viewed Gilead Sciences as facing ongoing downside pressure, with weak technical momentum and a limited outlook for near-term recovery. The current analysis builds on this by identifying a key technical level that could serve as a trigger for a directional shift, making it important for investors to closely monitor upcoming price action for signs of renewed strength or further weakness.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.